AstraZeneca Initiates Phase I/II Study of AZD4512 in B-cell Non-Hodgkin Lymphoma
AstraZeneca is conducting Phase I/II study to assess AZD4512 as monotherapy or in combination with other agents for relapsed/refractory B-NHL.
Asset / Drug
Drug and asset intelligence for AZD4512 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.